GSK’s Bid For Human Genome Sciences: A Deal Decades In The Making
This article was originally published in The Pink Sheet Daily
GlaxoSmithKline swoops in to acquire its research partner Human Genome Sciences – made vulnerable by the weak launch of Benlysta – for $13 per share in cash, or about $2.6 billion.
You may also be interested in...
After three months of battling, with lupus drug Benlysta still struggling, Human Genome Sciences accepted a modestly increased sales offer from partner GlaxoSmithKline.
Two former biotech high flyers are up for sale, with Amylin attracting more would-be suitors than Human Genome Sciences. The spectacle of the bidding is great. But did you know that the orphan drug company Alexion is worth more than those two companies combined?
GSK/Human Genome story takes a sharp turn, but does the big pharma’s hostile bid expose greater interest in cardiovascular drug darapladib than it is admitting?